Liver Cancer Clinical Trial
Official title:
A Study of the Safety Profile of Three Escalating Radioactivity Levels of 32P BioSilicon Delivered With the SIMPL Needle as Intratumoural Implantations in Patients With Unresectable Hepatocellular Carcinoma
Verified date | October 2005 |
Source | pSiVida Limited |
Contact | n/a |
Is FDA regulated | No |
Health authority | Singapore: Health Sciences Authority |
Study type | Interventional |
Brachytherapy is a recent technique used in the treatment of tumours and involves the use of
radioactive sources brought into close contact with the target tissues. One of the principal
benefits of brachytherapy is that high radiation doses can be localised within the tumour
with the consequence of minimal side effects. 32P is a radionuclide ideal for brachytherapy
as it has high energy beta emitting properties, typically a maximum tissue range of about 8
mm and a half life of 14.3 days. 32P BioSiliconTM is an active implantable medical device
encapsulating 32P within the internal microcrystalline structure of highly pure inert
silicon and acts as a sealed source for the provision of 32 phosphorous.
Tumours targeted with 32P BioSiliconTM are hypothesized to show a reduction in volume with a
low incidence of side effects associated with the treatment. Prolongation of survival and
improved quality of life would be favourable outcomes of the investigational product.
Status | Active, not recruiting |
Enrollment | 50 |
Est. completion date | February 2007 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Written informed consent. 2. Male or female patients equal to or greater than 18 years old. 3. Patients with diagnosis of hepatocellular carcinoma (HCC) meeting one of the criteria below: 1. Histology OR 2. Radiological evidence'*' of HCC demonstrated by dynamic contrast enhanced computed tomography (CT) or dynamic contrast enhanced magnetic resonance imaging (MRI) >/ 1cm AND serum AFP of at least 400 mcg/L OR 3. Radiological evidence'*' of HCC demonstrated by dynamic contrast CT or dynamic contrast enhanced MRI >/ 1cm AND serology positive for hepatitis B or C infection. '*' Criteria for radiological evidence of HCC are: central enhancement on hepatic arterial phase AND wash out on portal venous or delayed phase. 4. Hepatic tumour mass not amenable to surgical resection or patient refuses surgery. 5. ECOG performance status 0 - 2. 6. Okuda stage I - II 7. Total volume of any single treatable tumour not more than 65 cc (not more than approximately 5 cm in longest dimension). 8. Total treatable volume of not more than 125 cc (Group 1), 111 cc (Group 2), 139 cc (Group 3) - as defined by maximum radioactivity level (MBq) for the respective groups. 9. Adequate haematological, renal and hepatic functions as defined by the following laboratory values obtained within 14 days prior to Visit 2 - Absolute granulocyte count (AGC) >/1500 cells/mm3 - Serum creatinine < 2 times upper limit of normal (ULN) - Serum bilirubin < 3 times ULN - ALT (SGPT) < 5 times ULN and/or AST (SGOT) < 5 times ULN within 24 hours prior to implantation (Supportive care and correction permitted) Platelet count >/ 60,000/mm3 (60 x 10^9/L) - Prothrombin time < 3 seconds prolonged 10. Women of childbearing potential must have a negative urine pregnancy test within three days of Visit 2. 11. Contraception must be used (both male and female) for six months after implantation and during the duration of the whole study. 12. Patients must be accessible for treatment and follow up. Exclusion Criteria: 1. Clinical encephalopathy 2. Patients younger than 18 years old. 3. No life threatening tumours in other sites (e.g. brain) 4. Less than four weeks after local therapy with radiofrequency ablation (RFA), or ethanol, and less than six weeks after local therapy with transarterial chemoembolization therapy (TACE), or since prior chemotherapy or biologic therapy (e.g. immunotherapy, systemic vaccine therapy). 5. Prior radiotherapy to liver, pancreas or gastrointestinal tract. 6. Total volume for each tumour is greater than 65 cc (greater than approximately 5 cm in longest dimension). 7. Amenable to surgery. 8. Pregnant or lactating females. 9. Other diagnosed malignancy within the last five years, which may impact on study outcome. 10. Life expectancy of less than 12 weeks. 11. Patients with a significant history of cardiac disease, that is, uncontrolled high blood pressure, unstable angina, congestive heart failure, myocardial infarction within the past three months and cardiac ventricular arrhythmias requiring medication. 12. Patients with serious active infection or other serious underlying medical conditions that would impair the ability of the patient to receive protocol treatment at implantation visits. 13. Patients with any condition (e.g. psychological) that does not permit compliance with the protocol. 14. Patients who are known to be HIV positive. Testing is not required in the absence of clinical signs and symptoms suggestive of HIV infection. |
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Singapore | Singapore General Hospital | Outram Road |
Lead Sponsor | Collaborator |
---|---|
pSiVida Limited | pSiOncology Private Limited |
Singapore,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | This is a multicentre, open label study to evaluate the safety and efficacy of three escalating radioactivity levels (MBq) of 32P BioSiliconTM in patients with unresectable hepatocellular carcinoma | |||
Secondary | To evaluate the safety profile of three escalating radioactivity levels (MBq) of 32P BioSiliconTM given as intratumoural implantations in patients with unresectable hepatocellular carcinoma | |||
Secondary | To evaluate the systemic distribution of 32P BioSiliconTM and soluble P32, following the intratumoural implantations | |||
Secondary | To evaluate the safety and performance of the SIMPLTM needle | |||
Secondary | To evaluate the target tumour response of three escalating radioactivity levels (MBq) of 32P BioSiliconTM | |||
Secondary | To evaluate the duration of target tumour response and overall survival rates | |||
Secondary | To evaluate the association between tumour marker serum alpha-fetoprotein (AFP) and target tumour response with the three radioactivity levels (MBq) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03213314 -
HepaT1ca: Quantifying Liver Health in Surgical Candidates for Liver Malignancies
|
N/A | |
Not yet recruiting |
NCT04931420 -
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
|
Phase 2 | |
Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03756597 -
PAN-study: Pan-Cancer Early Detection Study (PAN)
|
||
Recruiting |
NCT05160740 -
Indocyanine Green Molecular Fluorescence Imaging Technique Using in Diagnosis and Treatment of Primary Liver Cancer
|
N/A | |
Completed |
NCT01906021 -
Study of New Software Used During Ablations
|
N/A | |
Terminated |
NCT04589884 -
Intraoperative EXamination Using MAChine-learning-based HYperspectral for diagNosis & Autonomous Anatomy Assessment
|
||
Recruiting |
NCT05953337 -
Radioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC)
|
N/A | |
Enrolling by invitation |
NCT04466124 -
Prospective Cohort Study of Liver Cancer Patients Treated With Proton Beam Therapy
|
||
Not yet recruiting |
NCT04053231 -
Hepatocarcinoma Recurrence on the Liver Study - Part2
|
||
Active, not recruiting |
NCT02869217 -
Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors
|
Phase 1 | |
Completed |
NCT03059238 -
Parecoxib Versus Celecoxib Versus Oxycodone in Pain Control for Transcatheter Chemoembolization Procedure
|
Phase 3 | |
Recruiting |
NCT02632188 -
Radical Surgery Followed by Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen for the Treatment of Hepatocellular Carcinoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT01388101 -
Real-time Diagnosis of Serum LECT 2 in Patient With Liver Cancer Using Electronic Antibody Sensor (e- Ab Sensor)
|
N/A | |
Completed |
NCT01042041 -
Sorafenib Tosylate and Chemoembolization in Treating Patients With Unresectable Liver Cancer
|
Phase 1 | |
Completed |
NCT00980239 -
HAI Irinotecan + IV Bevacizumab, Bevacizumab & Oxaliplatin or Bevacizumab & Cetuximab in Advanced Cancers Metastatic to Liver
|
Phase 1 | |
Terminated |
NCT00903396 -
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
|
Phase 2 | |
Completed |
NCT00790569 -
Varenicline or Nicotine Patch and Nicotine Gum in Helping Smokers in a Methadone Treatment Program Stop Smoking
|
N/A | |
Completed |
NCT00543777 -
Magnetic Resonance Elastography and 2-Point Dixon MR Imaging Techniques in Diffuse Liver Disease
|
Phase 1/Phase 2 | |
Terminated |
NCT00896467 -
Psychological and Emotional Impact in Patients Undergoing Treatment For Metastatic Cancer Either in a Clinical Trial or as Standard Off-Trial Therapy
|
N/A |